- Elizabeth S Klings, MD
Elizabeth S Klings, MD
- Associate Professor of Medicine
- Boston University School of Medicine
Cor pulmonale is a common complication of pulmonary hypertension. Its etiology, natural history, clinical features, diagnosis, treatment, and outcomes are reviewed here. The etiology, classification, pathogenesis, clinical manifestations, diagnosis, and treatment of pulmonary hypertension are discussed separately. (See "Overview of pulmonary hypertension in adults" and "Clinical features and diagnosis of pulmonary hypertension in adults" and "Pathogenesis of pulmonary hypertension" and "Treatment of pulmonary hypertension in adults".)
Cor pulmonale refers to the altered structure (eg, hypertrophy or dilatation) and/or impaired function of the right ventricle that results from pulmonary hypertension that is associated with diseases of the lung (eg, chronic obstructive pulmonary disease), vasculature (eg, idiopathic pulmonary arterial hypertension), upper airway (eg, obstructive sleep apnea), or chest wall (eg, kyphoscoliosis). Right-sided heart disease due to left-sided heart disease or congenital heart disease is NOT considered cor pulmonale [1-3].
It is important to note that there are conflicting opinions about the precise definition of cor pulmonale. According to some resources, altered structure and/or function of the right ventricle due to pulmonary vascular disease is not considered cor pulmonale. In other words, the resources only consider right ventricle abnormality due to lung disease, impaired ventilation, or environmental hypoxia to be cor pulmonale. We elected to use the definition that includes pulmonary vascular disease as a cause of cor pulmonale in this review because we felt that this would provide a broader overview of the diagnosis and treatment of such right ventricular disease.
The World Health Organization classifies patients with pulmonary hypertension into five groups based upon etiology . Patients in the first group (Group 1) are considered to have pulmonary arterial hypertension (PAH), while patients in the remaining four groups are considered to have pulmonary hypertension (PH). Cor pulmonale may be associated with any of the etiologies that cause Group 1 PAH (other than left-to-right shunt), Group 3 PH, Group 4 PH, or Group 5 PH (table 1). The most common causes of cor pulmonale are highlighted in this section.
●Chronic obstructive pulmonary disease (COPD) is the most common cause of cor pulmonale in North America [1,2]. It has been estimated that as many as 20 to 30 percent of patients with COPD have cor pulmonale . The severity of cor pulmonale appears to correlate with the magnitude of hypoxemia, hypercapnia, and airflow obstruction, as suggested by a study that found right ventricular hypertrophy in 40 percent of patients with an FEV1 <1.0L and 70 percent of patients with an FEV1 <0.6L . In most patients with COPD, cor pulmonale tends to be accompanied by mild pulmonary hypertension (ie, mean pulmonary artery pressure ≤40 mmHg).
- MacNee W. Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part One. Am J Respir Crit Care Med 1994; 150:833.
- Budev MM, Arroliga AC, Wiedemann HP, Matthay RA. Cor pulmonale: an overview. Semin Respir Crit Care Med 2003; 24:233.
- MacNee W. Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part two. Am J Respir Crit Care Med 1994; 150:1158.
- Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62:D34.
- Naeije R. Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2:20.
- McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009; 119:2250.
- Bradley TD, Rutherford R, Grossman RF, et al. Role of daytime hypoxemia in the pathogenesis of right heart failure in the obstructive sleep apnea syndrome. Am Rev Respir Dis 1985; 131:835.
- Yildiz OA, Onen ZP, Sen E, et al. Predictors of long-term survival in patients with chronic obstructive pulmonary disease. Saudi Med J 2006; 27:1866.
- Song JW, Song JK, Kim DS. Echocardiography and brain natriuretic peptide as prognostic indicators in idiopathic pulmonary fibrosis. Respir Med 2009; 103:180.
- Baudouin SV. Oedema and cor pulmonale revisited. Thorax 1997; 52:401.
- Morrison DA, Klein C, Welsh CH. Relief of right ventricular angina and increased exercise capacity with long-term oxygen therapy. Chest 1991; 100:534.
- Mesquita SM, Castro CR, Ikari NM, et al. Likelihood of left main coronary artery compression based on pulmonary trunk diameter in patients with pulmonary hypertension. Am J Med 2004; 116:369.
- Han MK, McLaughlin VV, Criner GJ, Martinez FJ. Pulmonary diseases and the heart. Circulation 2007; 116:2992.
- Watz H, Waschki B, Meyer T, et al. Decreasing cardiac chamber sizes and associated heart dysfunction in COPD: role of hyperinflation. Chest 2010; 138:32.
- Nishimura K, Nishimura T, Onishi K, et al. Changes in plasma levels of B-type natriuretic peptide with acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2014; 9:155.
- Seeger W, Adir Y, Barberà JA, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 2013; 62:D109.
- Incalzi RA, Fuso L, De Rosa M, et al. Electrocardiographic signs of chronic cor pulmonale: A negative prognostic finding in chronic obstructive pulmonary disease. Circulation 1999; 99:1600.
- CAIRD FI, STANFIELD CA. The electrocardiogram in asphyxial and in embolic acute cor pulmonale. Br Heart J 1962; 24:313.
- Burrows B, Kettel LJ, Niden AH, et al. Patterns of cardiovascular dysfunction in chronic obstructive lung disease. N Engl J Med 1972; 286:912.
- Benza R, Biederman R, Murali S, Gupta H. Role of cardiac magnetic resonance imaging in the management of patients with pulmonary arterial hypertension. J Am Coll Cardiol 2008; 52:1683.
- Zangiabadi A, De Pasquale CG, Sajkov D. Pulmonary hypertension and right heart dysfunction in chronic lung disease. Biomed Res Int 2014; 2014:739674.
- Andersen CU, Mellemkjær S, Nielsen-Kudsk JE, et al. Pulmonary hypertension in chronic obstructive and interstitial lung diseases. Int J Cardiol 2013; 168:1795.
- Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980; 93:391.
- Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981; 1:681.
- Timms RM, Khaja FU, Williams GW. Hemodynamic response to oxygen therapy in chronic obstructive pulmonary disease. Ann Intern Med 1985; 102:29.
- Weitzenblum E, Sautegeau A, Ehrhart M, et al. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1985; 131:493.
- Sliwiński P, Hawrylkiewicz I, Górecka D, Zieliński J. Acute effect of oxygen on pulmonary arterial pressure does not predict survival on long-term oxygen therapy in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 146:665.
- Selinger SR, Kennedy TP, Buescher P, et al. Effects of removing oxygen from patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1987; 136:85.
- Hoeper MM, Andreas S, Bastian A, et al. Pulmonary hypertension due to chronic lung disease: updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol 2011; 154 Suppl 1:S45.
- Polić S, Rumboldt Z, Dujić Z, et al. Role of digoxin in right ventricular failure due to chronic cor pulmonale. Int J Clin Pharmacol Res 1990; 10:153.
- Mathur PN, Powles P, Pugsley SO, et al. Effect of digoxin on right ventricular function in severe chronic airflow obstruction. A controlled clinical trial. Ann Intern Med 1981; 95:283.
- McLaughlin VV, Shah SJ, Souza R, Humbert M. Management of pulmonary arterial hypertension. J Am Coll Cardiol 2015; 65:1976.
- Lee-Chiong TL, Matthay RA.. The heart in the stable COPD patient.. In: Clinical management of chronic obstructive pulmonary disease., Similowski T, Whitelaw WA, Derenne JP. (Eds), Marcel Dekker, Inc., New York 2002. p.475.
- Lahm T, McCaslin CA, Wozniak TC, et al. Medical and surgical treatment of acute right ventricular failure. J Am Coll Cardiol 2010; 56:1435.
- Vizza CD, Rocca GD, Roma AD, et al. Acute hemodynamic effects of inhaled nitric oxide, dobutamine and a combination of the two in patients with mild to moderate secondary pulmonary hypertension. Crit Care 2001; 5:355.
- Bradford KK, Deb B, Pearl RG. Combination therapy with inhaled nitric oxide and intravenous dobutamine during pulmonary hypertension in the rabbit. J Cardiovasc Pharmacol 2000; 36:146.
- Khazin V, Kaufman Y, Zabeeda D, et al. Milrinone and nitric oxide: combined effect on pulmonary artery pressures after cardiopulmonary bypass in children. J Cardiothorac Vasc Anesth 2004; 18:156.
- Grinstein J, Gomberg-Maitland M. Management of pulmonary hypertension and right heart failure in the intensive care unit. Curr Hypertens Rep 2015; 17:32.
- Campo A, Mathai SC, Le Pavec J, et al. Outcomes of hospitalisation for right heart failure in pulmonary arterial hypertension. Eur Respir J 2011; 38:359.